The accreditors of this session require that you periodically check in to verify that you are still attentive.
Please click the button below to indicate that you are.
A recent AABB Chief Medical Officers’ roundtable discussion has brought platelet supply concerns to the forefront. The session is intended to raise awareness about the need to consider lowering the dose of apheresis platelets in the United States. It will start with an examination of the international minimum doses of both whole blood derived and apheresis platelets. A speaker from Canadian Blood Service will discuss their experience working with Health Canada to lower the dose to 2.4 x 1011 and standardizing the dose for all types of platelets (whole-blood and apheresis) and ease supply concerns. Demand data and customer complaints post-implementation will then be presented. The second speaker will present current regulatory dose requirements for apheresis and whole blood derived platelets. The session will conclude with a discussion on future directions and pathways for consideration of changing the platelet dose in the US.
All relevant financial relationships have been mitigated.
Learning Objectives:
Examine international minimum doses of both whole blood derived and apheresis platelets
State how Canadian Blood Services was able to work with Health Canada to standardize and lower the minimum platelet dose and ease supply concerns.
Define the current US FDA regulatory dose requirements for apheresis and whole blood derived platelets and pathways for consideration of changing the platelet dose in the US.
Speaker(s):
Prabhakar
Borge,
MD, PhD,
Memorial Sloan Kettering Cancer Center
Dana
V. Devine,
PhD,
Centre for Innovation, Canadian Blood Services
By completing the evaluation, you are attesting to watching the presentation in its entirety. A certificate will be immediately provided after submission.
Credits Available
AM22-16-O: (On-Demand) Lowering the Dose of Platelets – Is the Timing Right? The North American Perspective (Enduring) Evaluation